Serum β2-microglobulin concentration and its removal in patients treated with continuous ambulatory peritoneal dialysis

Hitoshi Kubo, Yoshindo Kawaguchi, Sumio Aizawa, Takashi Morita, Masaaki Nakayama, Yoshinori Wakabayashi, Shuuichi Watanabe, Aiichirou Ogawa, Osamu Sakai

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

This study was performed to clarify serum beta-2 microglobulin (β2-M) level and its change in 50 CAPD and 56 HD patients. There was significant correlation between duration of dialysis and serum β2-M level in CAPD and HD patients treated under 12 months, but no correlation in those treated over 12 months. Serum β2-M level was 33.5±9.1 mg/1 in 45 CAPD patients treated over 12 months, and 46.2±21.1 mg/1 m 35 HD patients. In 26 CAPD patients treated over 12 months, clearance and removal of β2-M were 1.0±0.3ml/min and 43.0±17.8 mg/day. There was significant correlation between dwell time and β2-M removal (p<0.01), and these results suggested β2-M was removed by diffusion. Because CAPD treatment can lower serum β2-M level compared to HD, there is possibility that CAPD is useful at prevention of dialysis associated amyloidosis.

Original languageEnglish
Pages (from-to)419-426
Number of pages8
JournalThe Japanese Journal Of Nephrology
Volume32
Issue number4
DOIs
Publication statusPublished - 1990 Jan

Keywords

  • CAPD
  • amyloidosis
  • β2-microglobulin

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Serum β2-microglobulin concentration and its removal in patients treated with continuous ambulatory peritoneal dialysis'. Together they form a unique fingerprint.

Cite this